THE IMPACT OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN ON LONG-TERM DIABETES-RELATED COMPLICATIONS- A MODELING ANALYSIS IN TYPE 1 DIABETES PATIENTS IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN
Author(s)
Manuela Helena Gschwend, PhD, Health Economist1, Mark Aagren, MSc, International Pricing Manager2, William J Valentine, PhD, Head of Operations11IMS Health, Allschwil, Switzerland; 2 Novo Nordisk A/S, Virum, Denmark
Presentation Documents
OBJECTIVES: The aim of this analysis was to evaluate the time to onset and long-term cumulative incidence of diabetes-related complications in type 1 diabetes patients receiving either insulin detemir or Neutral Protamine Hagedorn (NPH) insulin in combination with mealtime insulin aspart in five countries (Belgium, France, Germany, Italy and Spain). METHODS: A published and validated computer simulation model of diabetes (CORE Diabetes Model) was used to make long-term projections of clinical outcomes, based on patient characteristics and treatment effects from a 2-year, multi-national, open-label, randomized, controlled trial. In the trial, insulin detemir was associated with significant improvements in glycemic control after 24 months (HbA1c 7.36% versus 7.58%, mean difference ‑0.22%, P=0.022) and major hypoglycemic events (69% risk reduction, P=0.001) versus NPH. Patients treated with detemir gained less weight (1.7 versus 2.7 kg, P=0.024). Events were projected for a time horizon of 50 years. RESULTS: Basal-bolus therapy with insulin detemir was projected to improve mean life expectancy by 0.09 years (12.80 versus 12.71 years) versus NPH in Germany. Similar benefits were observed in the other countries (Belgium +0.14, France +0.13, Italy +0.15 and Spain +0.07 years). The time to onset of any diabetes-related complication was delayed by 0.08 years in the detemir arm (1.18 versus 1.10 years). Time to onset and cumulative incidence (CI) of diabetic eye and renal disease, neuropathy and amputations were generally decreased for detemir-based therapy, with greatest benefits observed in renal disease. The CIs of heart failure, angina and stroke were slightly raised in the detemir-based treatment arm as overall survival was increased, exposing these patients to a longer ongoing risk of these events. CONCLUSIONS: The modelling analysis suggests that insulin detemir is likely to improve life expectancy, delay the onset of and reduce the cumulative incidence of most diabetes related complications in type 1 diabetes patients.
Conference/Value in Health Info
2008-11, ISPOR Europe 2008, Athens, Greece
Value in Health, Vol. 11, No. 6 (November 2008)
Code
PDB1
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Diabetes/Endocrine/Metabolic Disorders